Catalog No.
DHK06402
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Clonality
Monoclonal
Target
Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
2.97 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NYJ7 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, AMG-757, CAS: 2307488-83-9
Clone ID
Tarlatamab
Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report., PMID:40499092
Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer., PMID:40496850
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy., PMID:40454646
Treatment of small cell lung cancer; advances and future prospects., PMID:40446464
Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies., PMID:40440602
ADCs and TCE in SCLC Therapy: The Beginning of a New Era?, PMID:40422520
The Path To Tarlatamab Approval: Leveraging Innovative Strategies and Global Regulatory Pathways., PMID:40419854
Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases., PMID:40280845
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer., PMID:40261494
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review., PMID:40260055
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy., PMID:40187110
Small Cell Lung Cancer: A Review., PMID:40163214
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors., PMID:40138603
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report., PMID:40126456
Taking a BiTE out of cancer., PMID:40122873
Top advances of the year: Small cell lung cancer., PMID:40040254
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial., PMID:40025391
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database., PMID:39982395
Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer., PMID:39877675
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer., PMID:39876075
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer., PMID:39759138
Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report., PMID:39757042
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer., PMID:39742708
Antibodies to watch in 2025., PMID:39711140
First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report., PMID:39619276
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study., PMID:39589690
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer., PMID:39530627
Recent advances in immunotherapy for small cell lung cancer., PMID:39526685
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer., PMID:39392556
'Tarlatamab's FDA approval: shaping the future of cancer therapy'., PMID:39359806
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report., PMID:39309421
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update., PMID:39208379
Tarlatamab: First Approval., PMID:39023700
Tarlatamab (Imdelltra) for small cell lung cancer., PMID:38981104
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients., PMID:38956984
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics., PMID:38927637
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy., PMID:38730427
Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel., PMID:38254746
Tarlatamab Shows Promise in SCLC., PMID:37877814
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer., PMID:37861218
Tarlatamab: a potential new option for recurrent small cell lung cancer., PMID:37577302
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic., PMID:37425422
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629
Taking it up a notch: a promising immunotherapy against small cell lung cancer., PMID:37323167
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?, PMID:37098228
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study., PMID:36689692
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons., PMID:36530878
For research use only. Not for human or drug use.
